Guangshengtang (300436.SZ): The Covid oral drug GST-HG171 has been approved for clinical trials with high viral inhibitory activity against multiple strains
Guangshengtang (300436.SZ): The Covid oral drug GST-HG171 has been approved for clinical trials with high viral inhibitory activity against multiple strains https://whatchinareads.com/article/?uid=14955ba23d3b11ed99bcc7030b3aab5e
2022-09-26: [Article Link] On 23 September 2022, the National Drug Supervisory Authority (NDSA) received a Notice of Approval for the Clinical Trial of Medicines (GST-HG171), an innovative drug such as APP News, Open Life Hall (300436.SZ), the company's Innovative Medicines Control Company, Fujian Guangzhengi Biotech Ltd. (“Hwangashi”)
Please
sign in to continue reading and access original article links of locked articles.
Subscribe now for full access.